- Location
Antibody Drug
"-
MHLW Has Approved Takeda Pharmaceutical's NDA of Adcetris 50mg Intended to Treat Patients
Jan 21, 2014The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...
-
Seattle Genetics Has Received Approval of ADCETRIS
Jan 18, 2014Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...
-
A New Combination of Drugs Might Prolong Life in Certain Older Leukemia Patients
Jan 10, 2014A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests. The research, led by German scientists, included nearly 800 older people (average age 73) who had been diagnosed with chronic ...
Tags: Drug, Drug Combo, Leukemia
-
Sutro Biopharma Has Entered Into a Collaboration Agreement
Jan 8, 2014Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration ...
Tags: Bispecific Antibodies, Sutro's Cell-Free Protein Synthesis Technology
-
AnaptysBio Has Commenced an Antibody Development Program with Momenta Pharmaceuticals
Dec 20, 2013US-based privately-held therapeutic antibody firm AnaptysBio has commenced an antibody development program with Momenta Pharmaceuticals, focused on the development of new antibodies against a therapeutically relevant target. Both the ...
-
Sutro Biopharma Has Received $26m in a Series D Financing
Dec 13, 2013Sutro Biopharma has received $26m in a Series D financing, which will be used for the expansion of its proprietary immuno-oncology product pipeline. The company is currently using its cell-free protein synthesis technology to develop new ...
-
Covagen Announced It Has Secured CHF42m in a Tranched Series B Financing
Dec 11, 2013Covagen has announced that the company has secured CHF42m in a tranched Series B financing with an option to obtain an additional CHF14m that would increase the total amount of the financing round to CHF56m. This financing will mainly ...
-
Roche and Molecular Partners Have Entered Into a Research Collaboration
Dec 9, 2013Roche and Molecular Partners have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular' DARPin biologics conjugated to toxic agents ...
Tags: Roche, Molecular Partners
-
SCT and ABB Have Entered Into a Collaboration to Identify New Therapeutic Antibodies
Nov 22, 2013Single Cell Technology (SCT) and AB Biosciences (ABB) have entered into a collaboration to identify new therapeutic antibodies. Under the deal, SCT will use its patented platform to screen plasma cells, measure the kinetics of secreted ...
-
Sorrento Therapeutics Announced a Definitive Agreement to Acquire Concortis Biosystems
Nov 18, 2013Sorrento Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive agreement to acquire US-based Concortis Biosystems. This acquisition provides Sorrento Therapeutics with a comprehensive technology platform for ...
-
The Patent Application Covers Synta's Proprietary HDC Technology
Nov 4, 2013Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...
-
AstraZeneca's Global Biologics Research Division Medimmune Will Acquire Spirogen
Oct 18, 2013AstraZeneca's global biologics research and development division MedImmune will acquire Spirogen, a biotech firm focused on antibody-drug conjugate technology for use in oncology. Spirogen's complete shares will be purchased by MedImmune ...
Tags: biologics research, AstraZeneca
-
BioInvent and Bayer Pharma Have Extended Their Collaboration to Develop Antibodies
Oct 16, 2013BioInvent International and Bayer Pharma have extended their collaboration to develop antibodies from BioInvent's n-CoDeR libraries. As part of the deal, which is an extension of the 2008 license agreement, Bayer will broaden its access ...
-
Develops Novel Anticancer Therapeutics Has Signed a Licensing Agreement with Novartis
Oct 15, 2013US-based biotechnology firm that develops novel anticancer therapeutics using antibody-drug conjugate (ADC) technology, ImmunoGen (IMGN) has signed a licensing agreement with Novartis, pursuant to which, Novartis has the exclusive right to ...
Tags: Immunogen, Novartis, ADC Technology
-
AnaptysBio Has Expanded Its Proprietary Immunotherapy Antibody Portfolio
Sep 3, 2013Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...
Tags: AnaptysBio, Antibody Portfolio
Related Products
-
Pet Insect Repellent Milbemycin Oxime CAS 129496-10-2 for Animal Medicine Deworming
-
HCV Antibody Test Uncut Sheet
-
HIV (1/2) Antibody Test Uhiv (1/2) Antibody Test Uncut Sheetncut Sheet
-
Syphilis Antibody Test Uncut Sheet
-
Infections Disease Test Syphilis Antibody Uncut Sheet with High Accuracy
-
Manufacturer Supply HCV Antibody Test Strips Uncut Sheet
